Kyverna Therapeutics (NASDAQ:KYTX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Kyverna Therapeutics (NASDAQ:KYTX) from a hold rating to a sell rating in a report issued on Saturday morning.

Other equities research analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, December 29th. Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a research report on Monday, December 15th. Wells Fargo & Company raised their price objective on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, HC Wainwright boosted their price objective on Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Stock Down 1.4%

Shares of NASDAQ:KYTX opened at $7.26 on Friday. The stock has a market capitalization of $317.96 million, a PE ratio of -1.95 and a beta of 3.45. The firm’s 50 day moving average price is $8.53 and its 200-day moving average price is $6.63. Kyverna Therapeutics has a twelve month low of $1.78 and a twelve month high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.12. Analysts expect that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Insider Transactions at Kyverna Therapeutics

In other Kyverna Therapeutics news, Director Beth C. Seidenberg bought 133,333 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average price of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the transaction, the director owned 869,317 shares of the company’s stock, valued at $6,519,877.50. This trade represents a 18.12% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Karen Marie Walker sold 23,998 shares of Kyverna Therapeutics stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the sale, the chief technology officer directly owned 22,636 shares in the company, valued at $276,159.20. This trade represents a 51.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Kyverna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new position in shares of Kyverna Therapeutics during the third quarter worth $28,000. Phoenix Wealth Advisors purchased a new stake in Kyverna Therapeutics in the 2nd quarter worth $32,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Kyverna Therapeutics during the 2nd quarter valued at about $37,000. Qube Research & Technologies Ltd purchased a new position in shares of Kyverna Therapeutics during the second quarter valued at about $43,000. Finally, Ethic Inc. bought a new stake in shares of Kyverna Therapeutics in the second quarter worth about $56,000. Institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.